在CYP2B6多态和非核酸逆转录酶抑制剂之间存在关联:药物诱导的肝损伤:系统性审查和元分析
Noppadol Chanhom1, Janjira Sonjan1, Jarupat Inchai1
1Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, 10400, Thailand.
Scientific reports
|November 28, 2024
概括
在CYP2B6的遗传变异影响抗逆转录病毒药物诱导的肝损伤 (ARVDILI) 的风险从非核糖逆转录酶抑制剂. 特定的CYP2B6多态增加EFV诱导的肝损伤风险,但降低NVP诱导的肝损伤风险.
科学领域:
- 药物基因组学 药物基因组学
- 肝病学 肝病学是一种肝病学.
- 药物新陈代谢 药物新陈代谢
背景情况:
- 尼维拉平 (NVP) 和埃法维伦兹 (EFV) 是用于HIV治疗的非核酸逆转录酶抑制剂 (NNRTIs).
- 这些药物可以导致抗逆转录病毒药物诱导的肝损伤 (ARVDILI),这是一个重大的临床问题.
- 了解影响ARVDILI的遗传因素对于个性化医学至关重要.
研究的目的:
- 系统地审查和分析与NNRTI诱导的肝损伤相关的药物基因组学现有数据.
- 确定关键基因及其与ARVDILI相关的相互作用.
- 具体分析CYP2B6遗传多态性与EFV和NVP诱导的肝损伤的关联.
主要方法:
- 对药物基因和ARVDILI的研究进行系统的文献搜索.
- 用STRING程序对已识别的基因进行蛋白质与蛋白质相互作用 (PPI) 分析.
- 与EFV和NVP肝损伤相关的CYP2B6多态的元分析,包括*1/*6和*6/*6基因型.
主要成果:
- 17个基因与ARVDILI有显著的关联.
- STRING分析确定了CYP2B6,CYP1A1和CYP2D6作为ARVDILI通路中的中心蛋白质.
- CYP2B6 *1/*6 和 *6/*6 多态性与EFV诱导的肝损伤风险增加有关.
- 相反,这些CYP2B6多态性与NVP诱导的肝损伤风险降低有关.
结论:
- CYP2B6遗传多态性与ARVDILI的敏感性有显著的相关性.
- 对CYP2B6变体的特定影响在efavirenz和nevirapine之间有所不同.
- 这些发现强调了药物基因组查对于优化NRTI治疗的重要性.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
84
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
84
Nonlinear Pharmacokinetics: Role of Transporters
33
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
33
Nonlinear Pharmacokinetics: Overview
278
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
278
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
30
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
30
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Nonlinear Pharmacokinetics: Causes of Nonlinearity
129
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
129


